{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:30:51Z","timestamp":1794000651119,"version":"4.8.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T00:00:00Z","timestamp":1629417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974053"],"award-info":[{"award-number":["81974053"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008838","name":"Shanghai Municipal Commission of Economy and Informatization","doi-asserted-by":"crossref","award":["18441902300"],"award-info":[{"award-number":["18441902300"]}],"id":[{"id":"10.13039\/501100008838","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An in-depth understanding of immune evasion mechanisms in tumors is crucial to overcome resistance and enable innovative advances in immunotherapy. Circular RNAs (circRNAs) have been implicated in cancer progression. However, much remains unknown regarding whether circRNAs impact immune escape in non-small-cell lung carcinoma (NSCLC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed bioinformatics analysis to profile and identify the circRNAs mediating immune evasion in NSCLC. A luciferase reporter assay, RNA immunoprecipitation (RIP), RNA pulldown assays and fluorescence in situ hybridization were performed to identify the interactions among circIGF2BP3, miR-328-3p, miR-3173-5p and plakophilin 3 (PKP3). In vitro T cell-mediated killing assays and in vivo syngeneic mouse models were used to investigate the functional roles of circIGF2BP3 and its downstream target PKP3 in antitumor immunity in NSCLC. The molecular mechanism of PKP3-induced PD-L1 upregulation was explored by immunoprecipitation, RIP, and ubiquitination assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We demonstrated that circIGF2BP3 (hsa_circ_0079587) expression was increased in NSCLC and negatively correlated with CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell infiltration. Functionally, elevated circIGF2BP3 inactivated cocultured T cells in vitro and compromised antitumor immunity in an immunocompetent mouse model, and this effect was dependent on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells. Mechanistically, METTL3 mediates the N\n                      <jats:sup>6<\/jats:sup>\n                      -methyladenosine (m\n                      <jats:sup>6<\/jats:sup>\n                      A) modification of circIGF2BP3 and promotes its circularization in a manner dependent on the m\n                      <jats:sup>6<\/jats:sup>\n                      A reader protein YTHDC1. circIGF2BP3 competitively upregulates PKP3 expression by sponging miR-328-3p and miR-3173-5p to compromise the cancer immune response. Furthermore, PKP3 engages with the RNA-binding protein FXR1 to stabilize OTUB1 mRNA, and OTUB1 elevates PD-L1 abundance by facilitating its deubiquitination. Tumor PD-L1 deletion completely blocked the impact of the circIGF2BP3\/PKP3 axis on the CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell response. The inhibition of circIGF2BP3\/PKP3 enhanced the treatment efficacy of anti-PD-1 therapy in a Lewis lung carcinoma mouse model. Collectively, the PKP3\/PD-L1 signature and the infiltrating CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell status stratified NSCLC patients into different risk groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Our results reveal the function of circIGF2BP3 in causing immune escape from CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell-mediated killing through a decrease in PD-L1 ubiquitination and subsequent proteasomal degradation by stabilizing OTUB1 mRNA in a PKP3-dependent manner. This work sheds light on a novel mechanism of PD-L1 regulation in NSCLC and provides a rationale to enhance the efficacy of anti-PD-1 treatment in NSCLC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-021-01398-4","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T02:04:07Z","timestamp":1629425047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":371,"title":["N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Zhenchuan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlang","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaorui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglai","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4093-5527","authenticated-orcid":false,"given":"Yongxin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"issue":"1","key":"1398_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/nrc3775","volume":"14","author":"Z Chen","year":"2014","unstructured":"Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535\u201346. https:\/\/doi.org\/10.1038\/nrc3775.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","volume":"83","author":"JR Molina","year":"2008","unstructured":"Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584\u201394. https:\/\/doi.org\/10.1016\/S0025-6196(11)60735-0.","journal-title":"Mayo Clin Proc"},{"issue":"21","key":"1398_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1501824.","journal-title":"N Engl J Med"},{"issue":"25","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377(25):2500\u20131. https:\/\/doi.org\/10.1056\/NEJMc1713444.","journal-title":"N Engl J Med"},{"issue":"6","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.immuni.2016.06.001","volume":"44","author":"JM Pitt","year":"2016","unstructured":"Pitt JM, Vetizou M, Daillere R, Roberti MP, Yamazaki T, Routy B, et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity. 2016;44(6):1255\u201369. https:\/\/doi.org\/10.1016\/j.immuni.2016.06.001.","journal-title":"Immunity"},{"issue":"1","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s13046-019-1192-1","volume":"38","author":"Y Chen","year":"2019","unstructured":"Chen Y, Liu Q, Chen Z, Wang Y, Yang W, Hu Y, et al. PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer. J Exp Clin Cancer Res. 2019;38(1):193. https:\/\/doi.org\/10.1186\/s13046-019-1192-1.","journal-title":"J Exp Clin Cancer Res"},{"issue":"23","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"6964","DOI":"10.1158\/0008-5472.CAN-16-0258","volume":"76","author":"CA Clark","year":"2016","unstructured":"Clark CA, Gupta HB, Sareddy G, Pandeswara S, Lao S, Yuan B, et al. Tumor-intrinsic PD-L1 signals regulate cell growth, pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer Res. 2016;76(23):6964\u201374. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-0258.","journal-title":"Cancer Res"},{"issue":"9","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1101\/gr.202895.115","volume":"26","author":"XO Zhang","year":"2016","unstructured":"Zhang XO, Dong R, Zhang Y, Zhang JL, Luo Z, Zhang J, et al. Diverse alternative back-splicing and alternative splicing landscape of circular RNAs. Genome Res. 2016;26(9):1277\u201387. https:\/\/doi.org\/10.1101\/gr.202895.115.","journal-title":"Genome Res"},{"issue":"7441","key":"1398_CR10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","volume":"495","author":"S Memczak","year":"2013","unstructured":"Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 2013;495(7441):333\u20138. https:\/\/doi.org\/10.1038\/nature11928.","journal-title":"Nature"},{"issue":"5","key":"1398_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nbt.2890","volume":"32","author":"WR Jeck","year":"2014","unstructured":"Jeck WR, Sharpless NE. Detecting and characterizing circular RNAs. Nat Biotechnol. 2014;32(5):453\u201361. https:\/\/doi.org\/10.1038\/nbt.2890.","journal-title":"Nat Biotechnol"},{"issue":"5","key":"1398_CR12","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/nrg.2016.20","volume":"17","author":"DW Thomson","year":"2016","unstructured":"Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016;17(5):272\u201383. https:\/\/doi.org\/10.1038\/nrg.2016.20.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"1398_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12943-019-0951-0","volume":"18","author":"H Su","year":"2019","unstructured":"Su H, Tao T, Yang Z, Kang X, Zhang X, Kang D, et al. Circular RNA cTFRC acts as the sponge of MicroRNA-107 to promote bladder carcinoma progression. Mol Cancer. 2019;18(1):27. https:\/\/doi.org\/10.1186\/s12943-019-0951-0.","journal-title":"Mol Cancer"},{"issue":"1","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13059-019-1685-4","volume":"20","author":"WC Liang","year":"2019","unstructured":"Liang WC, Wong CW, Liang PP, Shi M, Cao Y, Rao ST, et al. Translation of the circular RNA circbeta-catenin promotes liver cancer cell growth through activation of the Wnt pathway. Genome Biol. 2019;20(1):84. https:\/\/doi.org\/10.1186\/s13059-019-1685-4.","journal-title":"Genome Biol"},{"issue":"1","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1038\/s41467-017-01216-w","volume":"8","author":"CY Yu","year":"2017","unstructured":"Yu CY, Li TC, Wu YY, Yeh CH, Chiang W, Chuang CY, et al. The circular RNA circBIRC6 participates in the molecular circuitry controlling human pluripotency. Nat Commun. 2017;8(1):1149. https:\/\/doi.org\/10.1038\/s41467-017-01216-w.","journal-title":"Nat Commun"},{"issue":"11","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"2839","DOI":"10.1158\/0008-5472.CAN-17-2808","volume":"78","author":"M Qiu","year":"2018","unstructured":"Qiu M, Xia W, Chen R, Wang S, Xu Y, Ma Z, et al. The circular RNA circPRKCI promotes tumor growth in lung adenocarcinoma. Cancer Res. 2018;78(11):2839\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-2808.","journal-title":"Cancer Res"},{"issue":"1","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12935-020-01642-9","volume":"20","author":"X Xu","year":"2020","unstructured":"Xu X, Tao R, Sun L, Ji X. Exosome-transferred hsa_circ_0014235 promotes DDP chemoresistance and deteriorates the development of non-small cell lung cancer by mediating the miR-520a-5p\/CDK4 pathway. Cancer Cell Int. 2020;20(1):552. https:\/\/doi.org\/10.1186\/s12935-020-01642-9.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"1398_CR18","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tig.2019.12.007","volume":"36","author":"Y Lee","year":"2020","unstructured":"Lee Y, Choe J, Park OH, Kim YK. Molecular mechanisms driving mRNA degradation by m(6)a modification. Trends Genet. 2020;36(3):177\u201388. https:\/\/doi.org\/10.1016\/j.tig.2019.12.007.","journal-title":"Trends Genet"},{"issue":"11","key":"1398_CR19","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41419-020-03148-8","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu S, Li Q, Li G, Zhang Q, Zhuo L, Han X, et al. The mechanism of m(6)a methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by beta-elemene. Cell Death Dis. 2020;11(11):969. https:\/\/doi.org\/10.1038\/s41419-020-03148-8.","journal-title":"Cell Death Dis"},{"issue":"1","key":"1398_CR20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13045-019-0830-6","volume":"12","author":"D Jin","year":"2019","unstructured":"Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, et al. m(6)a mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis. J Hematol Oncol. 2019;12(1):135. https:\/\/doi.org\/10.1186\/s13045-019-0830-6.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1398_CR21","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bbrc.2018.11.163","volume":"508","author":"V Lim","year":"2019","unstructured":"Lim V, Zhu H, Diao S, Hu L, Hu J. PKP3 interactions with MAPK-JNK-ERK1\/2-mTOR pathway regulates autophagy and invasion in ovarian cancer. Biochem Biophys Res Commun. 2019;508(2):646\u201353. https:\/\/doi.org\/10.1016\/j.bbrc.2018.11.163.","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"1398_CR22","doi-asserted-by":"publisher","first-page":"4244","DOI":"10.1128\/MCB.00766-14","volume":"34","author":"R Fischer-Keso","year":"2014","unstructured":"Fischer-Keso R, Breuninger S, Hofmann S, Henn M, Rohrig T, Strobel P, et al. Plakophilins 1 and 3 bind to FXR1 and thereby influence the mRNA stability of desmosomal proteins. Mol Cell Biol. 2014;34(23):4244\u201356. https:\/\/doi.org\/10.1128\/MCB.00766-14.","journal-title":"Mol Cell Biol"},{"issue":"12","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/mc.22895","volume":"57","author":"Y Li","year":"2018","unstructured":"Li Y, Ju K, Wang W, Liu Z, Xie H, Jiang Y, et al. Dinitrosopiperazine-decreased PKP3 through upregulating miR-149 participates in nasopharyngeal carcinoma metastasis. Mol Carcinog. 2018;57(12):1763\u201379. https:\/\/doi.org\/10.1002\/mc.22895.","journal-title":"Mol Carcinog"},{"issue":"10","key":"1398_CR24","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000014608","volume":"98","author":"H Qian","year":"2019","unstructured":"Qian H, Yuan D, Bao J, Liu F, Zhang W, Yang X, et al. Increased expression of plakophilin 3 is associated with poor prognosis in ovarian cancer. Medicine (Baltimore). 2019;98(10):e14608. https:\/\/doi.org\/10.1097\/MD.0000000000014608.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1398_CR25","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9(1):559. https:\/\/doi.org\/10.1186\/1471-2105-9-559.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"1398_CR26","doi-asserted-by":"publisher","first-page":"3200","DOI":"10.1038\/s41467-019-11162-4","volume":"10","author":"Z Cheng","year":"2019","unstructured":"Cheng Z, Yu C, Cui S, Wang H, Jin H, Wang C, et al. circTP63 functions as a ceRNA to promote lung squamous cell carcinoma progression by upregulating FOXM1. Nat Commun. 2019;10(1):3200. https:\/\/doi.org\/10.1038\/s41467-019-11162-4.","journal-title":"Nat Commun"},{"issue":"22","key":"1398_CR27","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1158\/1078-0432.CCR-15-0685","volume":"21","author":"L Martinez-Lostao","year":"2015","unstructured":"Martinez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res. 2015;21(22):5047\u201356. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0685.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1398_CR28","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ymthe.2020.12.032","volume":"29","author":"X Hu","year":"2021","unstructured":"Hu X, Wang J, Chu M, Liu Y, Wang ZW, Zhu X. Emerging role of Ubiquitination in the regulation of PD-1\/PD-L1 in cancer immunotherapy. Mol Ther. 2021;29(3):908\u201319. https:\/\/doi.org\/10.1016\/j.ymthe.2020.12.032.","journal-title":"Mol Ther"},{"issue":"8","key":"1398_CR29","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1080\/15476286.2016.1227904","volume":"14","author":"D Lyu","year":"2017","unstructured":"Lyu D, Huang S. The emerging role and clinical implication of human exonic circular RNA. RNA Biol. 2017;14(8):1000\u20136. https:\/\/doi.org\/10.1080\/15476286.2016.1227904.","journal-title":"RNA Biol"},{"issue":"3","key":"1398_CR30","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2020.02.006","volume":"37","author":"H Liu","year":"2020","unstructured":"Liu H, Kuang X, Zhang Y, Ye Y, Li J, Liang L, et al. ADORA1 inhibition promotes tumor immune evasion by regulating the ATF3-PD-L1 Axis. Cancer Cell. 2020;37(3):324\u201339e328. https:\/\/doi.org\/10.1016\/j.ccell.2020.02.006.","journal-title":"Cancer Cell"},{"issue":"6","key":"1398_CR31","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","volume":"35","author":"D Dangaj","year":"2019","unstructured":"Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885\u2013900e810. https:\/\/doi.org\/10.1016\/j.ccell.2019.05.004.","journal-title":"Cancer Cell"},{"issue":"2","key":"1398_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1089\/dna.2020.6136","volume":"40","author":"W Guo","year":"2021","unstructured":"Guo W, Huai Q, Wan H, Guo L, Song P, Gao S, et al. Prognostic impact of IGF2BP3 expression in patients with surgically resected lung adenocarcinoma. DNA Cell Biol. 2021;40(2):316\u201331. https:\/\/doi.org\/10.1089\/dna.2020.6136.","journal-title":"DNA Cell Biol"},{"issue":"5","key":"1398_CR33","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/cr.2017.31","volume":"27","author":"Y Yang","year":"2017","unstructured":"Yang Y, Fan X, Mao M, Song X, Wu P, Zhang Y, et al. Extensive translation of circular RNAs driven by N(6)-methyladenosine. Cell Res. 2017;27(5):626\u201341. https:\/\/doi.org\/10.1038\/cr.2017.31.","journal-title":"Cell Res"},{"key":"1398_CR34","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3389\/fgene.2020.00994","volume":"11","author":"F Li","year":"2020","unstructured":"Li F, Wang H, Huang H, Zhang L, Wang D, Wan Y. m6A RNA methylation regulators participate in the malignant progression and have clinical prognostic value in lung adenocarcinoma. Front Genet. 2020;11:994. https:\/\/doi.org\/10.3389\/fgene.2020.00994.","journal-title":"Front Genet"},{"issue":"6","key":"1398_CR35","doi-asserted-by":"publisher","first-page":"107641","DOI":"10.1016\/j.celrep.2020.107641","volume":"31","author":"G Di Timoteo","year":"2020","unstructured":"Di Timoteo G, Dattilo D, Centron-Broco A, Colantoni A, Guarnacci M, Rossi F, et al. Modulation of circRNA metabolism by m(6)a modification. Cell Rep. 2020;31(6):107641. https:\/\/doi.org\/10.1016\/j.celrep.2020.107641.","journal-title":"Cell Rep"},{"key":"1398_CR36","doi-asserted-by":"crossref","unstructured":"Zhu D, Xu R, Huang X, Tang Z, Tian Y, Zhang J, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2020;28(6):1773\u201389.","DOI":"10.1038\/s41418-020-00700-z"},{"issue":"16","key":"1398_CR37","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2018100836","volume":"38","author":"IL Patop","year":"2019","unstructured":"Patop IL, Wust S, Kadener S. Past, present, and future of circRNAs. EMBO J. 2019;38(16):e100836. https:\/\/doi.org\/10.15252\/embj.2018100836.","journal-title":"EMBO J"},{"issue":"328","key":"1398_CR38","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8(328):328rv324.","journal-title":"Sci Transl Med"},{"key":"1398_CR39","doi-asserted-by":"crossref","unstructured":"Chen Y, Xu J, Wu X, Yao H, Yan Z, Guo T, et al. CD147 regulates antitumor CD8(+) T-cell responses to facilitate tumor-immune escape. Cell Mol Immunol. 2020;18(8):1995\u20132009.","DOI":"10.1038\/s41423-020-00570-y"},{"issue":"1","key":"1398_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-021-01333-7","volume":"20","author":"P Shen","year":"2021","unstructured":"Shen P, Yang T, Chen Q, Yuan H, Wu P, Cai B, et al. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing. Mol Cancer. 2021;20(1):51. https:\/\/doi.org\/10.1186\/s12943-021-01333-7.","journal-title":"Mol Cancer"},{"issue":"9","key":"1398_CR41","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.celrep.2017.08.027","volume":"20","author":"C Zhou","year":"2017","unstructured":"Zhou C, Molinie B, Daneshvar K, Pondick JV, Wang J, Van Wittenberghe N, et al. Genome-wide maps of m6A circRNAs identify widespread and cell-type-specific methylation patterns that are distinct from mRNAs. Cell Rep. 2017;20(9):2262\u201376. https:\/\/doi.org\/10.1016\/j.celrep.2017.08.027.","journal-title":"Cell Rep"},{"issue":"6","key":"1398_CR42","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41422-018-0040-8","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Hsu PJ, Chen YS, Yang YG. Dynamic transcriptomic m(6)a decoration: writers, erasers, readers and functions in RNA metabolism. Cell Res. 2018;28(6):616\u201324. https:\/\/doi.org\/10.1038\/s41422-018-0040-8.","journal-title":"Cell Res"},{"issue":"4","key":"1398_CR43","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/jcp.30023","volume":"236","author":"L Xue","year":"2021","unstructured":"Xue L, Li J, Lin Y, Liu D, Yang Q, Jian J, et al. M(6) a transferase METTL3-induced lncRNA ABHD11-AS1 promotes the Warburg effect of non-small-cell lung cancer. J Cell Physiol. 2021;236(4):2649\u201358. https:\/\/doi.org\/10.1002\/jcp.30023.","journal-title":"J Cell Physiol"},{"issue":"3","key":"1398_CR44","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1007\/s12032-011-0071-1","volume":"29","author":"GG Demirag","year":"2012","unstructured":"Demirag GG, Sullu Y, Yucel I. Expression of Plakophilins (PKP1, PKP2, and PKP3) in breast cancers. Med Oncol. 2012;29(3):1518\u201322. https:\/\/doi.org\/10.1007\/s12032-011-0071-1.","journal-title":"Med Oncol"},{"issue":"9","key":"1398_CR45","doi-asserted-by":"publisher","first-page":"995","DOI":"10.14670\/HH-11-996","volume":"33","author":"S Masic","year":"2018","unstructured":"Masic S, Brcic L, Kruslin B, Sepac A, Pigac B, Stancic-Rokotov D, et al. Expression of plakophilin 3 in diffuse malignant pleural mesothelioma. Histol Histopathol. 2018;33(9):995\u20131004. https:\/\/doi.org\/10.14670\/HH-11-996.","journal-title":"Histol Histopathol"},{"key":"1398_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bbrc.2021.02.029","volume":"550","author":"J Lu","year":"2021","unstructured":"Lu J, Lin J, Zhou Y, Ye K, Fang C. MiR-328-3p inhibits lung adenocarcinoma-genesis by downregulation PYCR1. Biochem Biophys Res Commun. 2021;550:99\u2013106. https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.029.","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"1398_CR47","doi-asserted-by":"publisher","first-page":"31651","DOI":"10.1038\/srep31651","volume":"6","author":"W Ma","year":"2016","unstructured":"Ma W, Ma CN, Zhou NN, Li XD, Zhang YJ. Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy. Sci Rep. 2016;6(1):31651. https:\/\/doi.org\/10.1038\/srep31651.","journal-title":"Sci Rep"},{"issue":"1","key":"1398_CR48","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s40425-019-0696-8","volume":"7","author":"ZQ Zhou","year":"2019","unstructured":"Zhou ZQ, Zhao JJ, Pan QZ, Chen CL, Liu Y, Tang Y, et al. PD-L1 expression is a predictive biomarker for CIK cell-based immunotherapy in postoperative patients with breast cancer. J Immunother Cancer. 2019;7(1):228. https:\/\/doi.org\/10.1186\/s40425-019-0696-8.","journal-title":"J Immunother Cancer"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-021-01398-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01398-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T02:04:19Z","timestamp":1629425059000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01398-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01398-4","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,20]]},"assertion":[{"value":"27 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of Shanghai Tongji Hospital. Informed consent was obtained from each patient before enrollment in this study. All animal experiments were approved by the Animal Care and Use Committee of Shanghai Tongji Hospital and conducted in accordance with ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}